Document:

Form of Warrant Agreement dated 9/4/07

 Exhibit 10.30 
 Execution Version  
 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED
UPON ITS 
 EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON 
 TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT AND 
 IN SECTION 4 OF THE THIRD AMENDED AND RESTATED
 
 STOCK RESTRICTION AGREEMENT DATED AS OF SEPTEMBER 4, 2007 
  

			
	Warrant No. D-        	  	Number of Shares:                     
		  	(subject to adjustment)
	Date of Issuance: September 4, 2007	  	
		
	 Original Issue Date (as defined in subsection
 2(a)): September 4, 2007
	  	

 Elixir Pharmaceuticals, Inc. 
 Common Stock Purchase Warrant 
 (Void after September 4, 2014) 

Elixir Pharmaceuticals, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that
                            , or its registered assigns (the “Registered Holder”), is
entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the date of issuance and on or before 5:00 p.m. (Boston time) on September 4, 2014,
                 shares of Common Stock, $0.001 par value per share, of the Company (“Common Stock”), at a purchase price of $0.01 per share. The shares
purchasable upon exercise of this Warrant, and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Shares” and the “Purchase
Price,” respectively. 
 1. Exercise. 
 (a) Exercise for Cash. The Registered Holder may, at its option, elect to exercise this Warrant, in whole or in part and at any time or from time to time, by surrendering this Warrant, with the purchase form
appended hereto as Exhibit I duly executed by or on behalf of the Registered Holder, at the principal office of the Company, or at such other office or agency as the Company may designate, accompanied by payment in full, in lawful money
of the United States, of the Purchase Price payable in respect of the number of Warrant Shares purchased upon such exercise. 
 (b)
Cashless Exercise. 
 (i) The Registered Holder may, at its option, elect to exercise this Warrant, in whole or in part and at any
time or from time to time, on a cashless basis, by surrendering this Warrant, with the purchase form appended hereto as Exhibit I duly executed by or on behalf of the Registered Holder, at the principal office of the Company, or at such other office
or agency as the Company may designate, by canceling a portion of this Warrant in payment of the Purchase Price payable in respect of the number of Warrant Shares purchased upon such exercise. In the event of an exercise pursuant to this subsection
1(b), the number of Warrant Shares issued to the Registered Holder shall be determined according to the following formula: 

					
	X  =	 	Y(A-B)	  	
		 	A    	  	
			
	Where:	 	X =	  	the number of Warrant Shares that shall be issued to the Registered Holder;
			
		 	Y =	  	the number of Warrant Shares for which this Warrant is being exercised (which shall include both the number of Warrant Shares issued to the Registered Holder and the number of Warrant Shares
subject to the portion of the Warrant being cancelled in payment of the Purchase Price);
			
		 	A =	  	the Fair Market Value (as defined below) of one share of Common Stock; and
			
		 	B =	  	the Purchase Price then in effect.

 (ii) The Fair Market Value per share of Common Stock shall be determined as follows: 

(1) If the Common Stock is listed on a national securities exchange or a nationally recognized trading system as of the Exercise Date, the Fair Market
Value per share of Common Stock shall be deemed to be the average of the high and low reported sale prices per share of Common Stock thereon on the trading day immediately preceding the Exercise Date (provided that if no such price is
reported on such day, the Fair Market Value per share of Common Stock shall be determined pursuant to clause (2)). 
 (2) If the Common
Stock is not listed on a national securities exchange or a nationally recognized trading system as of the Exercise Date, the Fair Market Value per share of Common Stock shall be deemed to be the amount most recently determined by the Board of
Directors of the Company (the “Board”) to represent the Fair Market Value per share of the Common Stock (including without limitation a determination for purposes of granting Common Stock options or issuing Common Stock under any plan,
agreement or arrangement with employees of the Company); and, upon request of the Registered Holder, the Board (or a representative thereof) shall, as promptly as reasonably practicable but in any event not later than ten (10) days after such
request, notify the Registered Holder of the Fair Market Value per share of Common Stock and furnish the Registered Holder with reasonable documentation of the Board’s determination of such Fair Market Value. Notwithstanding the foregoing, if
the Board has not made such a determination within the three-month period prior to the Exercise Date, then (A) the Board shall make, and shall provide or cause to be provided to the Registered Holder notice of, a determination of the Fair
Market Value per share of the Common Stock within fifteen (15) days of a request by the Registered Holder that it do so, and (B) the exercise of this Warrant pursuant to this subsection 1(b) shall be delayed until such determination is
made and notice thereof is provided to the Registered Holder. 
  

 - 2 - 

 (c) Exercise Date. Each exercise of this Warrant shall be deemed to have been effected immediately
prior to the close of business on the day on which this Warrant shall have been surrendered to the Company as provided in subsection 1(a) or 1(b) above (the “Exercise Date”). At such time, the person or persons in whose name or names any
certificates for Warrant Shares shall be issuable upon such exercise as provided in subsection 1(d) below shall be deemed to have become the holder or holders of record of the Warrant Shares represented by such certificates. 
 (d) Issuance of Certificates. As soon as practicable after the exercise of this Warrant in whole or in part, and in any event within ten
(10) days thereafter, the Company, at its expense, will cause to be issued in the name of, and delivered to, the Registered Holder, or as the Registered Holder (upon payment by the Registered Holder of any applicable transfer taxes) may direct:

 (i) a certificate or certificates for the number of full Warrant Shares to which the Registered Holder shall be entitled upon such
exercise plus, in lieu of any fractional share to which the Registered Holder would otherwise be entitled, cash in an amount determined pursuant to Section 3 hereof; and 
 (ii) in case such exercise is in part only, a new warrant or warrants (dated the date hereof) of like tenor, calling in the aggregate on the face or
faces thereof for the number of Warrant Shares equal (without giving effect to any adjustment therein) to the number of such shares called for on the face of this Warrant minus the number of Warrant Shares for which this Warrant was so exercised
(which, in the case of an exercise pursuant to subsection 1(b), shall include both the number of Warrant Shares issued to the Registered Holder pursuant to such partial exercise and the number of Warrant Shares subject to the portion of the
Warrant being cancelled in payment of the Purchase Price). 
 2. Adjustments. 
 (a) Adjustment for Stock Splits and Combinations. If the Company shall at any time or from time to time after the date on which this Warrant was
first issued (or, if this Warrant was issued upon partial exercise of, or in replacement of, another warrant of like tenor, then the date on which such original warrant was first issued) (either such date being referred to as the “Original
Issue Date”) effect a subdivision of the outstanding Common Stock, the Purchase Price then in effect immediately before that subdivision shall be proportionately decreased. If the Company shall at any time or from time to time after the
Original Issue Date combine the outstanding shares of Common Stock, the Purchase Price then in effect immediately before the combination shall be proportionately increased. Any adjustment under this paragraph shall become effective at the close of
business on the date the subdivision or combination becomes effective. 
 (b) Adjustment for Certain Dividends and Distributions. In
the event the Company at any time, or from time to time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in
additional shares of Common Stock, then and in each such event the Purchase Price then in effect immediately before such event shall be decreased as 

  

 - 3 - 

 
of the time of such issuance or, in the event such a record date shall have been fixed, as of the close of business on such record date, by multiplying the
Purchase Price then in effect by a fraction: 
 (1) the numerator of which shall be the total number of shares of Common Stock issued and
outstanding immediately prior to the time of such issuance or the close of business on such record date, and 
 (2) the denominator of which
shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or
distribution; 
 provided, however, that if such record date shall have been fixed and such dividend is not fully paid or if such distribution
is not fully made on the date fixed therefor, the Purchase Price shall be recomputed accordingly as of the close of business on such record date and thereafter the Purchase Price shall be adjusted pursuant to this paragraph as of the time of actual
payment of such dividends or distributions. 
 (c) Adjustment in Number of Warrant Shares. When any adjustment is required to be made
in the Purchase Price pursuant to subsections 2(a) or 2(b), the number of Warrant Shares purchasable upon the exercise of this Warrant shall be changed to the number determined by dividing (i) an amount equal to the number of shares
issuable upon the exercise of this Warrant immediately prior to such adjustment, multiplied by the Purchase Price in effect immediately prior to such adjustment, by (ii) the Purchase Price in effect immediately after such adjustment.

 (d) Adjustments for Other Dividends and Distributions. In the event the Company at any time or from time to time after the Original
Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Company (other than shares of Common Stock) or in cash or other
property (other than regular cash dividends paid out of earnings or earned surplus, determined in accordance with generally accepted accounting principles), then and in each such event provision shall be made so that the Registered Holder shall
receive upon exercise hereof, in addition to the number of shares of Common Stock issuable hereunder, the kind and amount of securities of the Company, cash or other property which the Registered Holder would have been entitled to receive had this
Warrant been exercised on the date of such event and had the Registered Holder thereafter, during the period from the date of such event to and including the Exercise Date, retained any such securities receivable during such period, giving
application to all adjustments called for during such period under this Section 2 with respect to the rights of the Registered Holder. 
 (e) Adjustment for Reorganization. If there shall occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Company in which the Common Stock is converted into or exchanged for securities,
cash or other property (other than a transaction covered by subsections 2(a), 2(b) or 2(d)) (collectively, a “Reorganization”), then, following such Reorganization, the Registered Holder shall receive upon exercise hereof the kind

  

 - 4 - 

 
and amount of securities, cash or other property which the Registered Holder would have been entitled to receive pursuant to such Reorganization if such
exercise had taken place immediately prior to such Reorganization. Notwithstanding the foregoing sentence, if (x) there shall occur any Reorganization in which the Common Stock is converted into or exchanged for anything other than solely
equity securities, and (y) the common stock of the acquiring or surviving company is publicly traded, then, as part of such Reorganization, (i) the Registered Holder shall have the right thereafter to receive upon the exercise hereof such
number of shares of common stock of the acquiring or surviving company as is determined by multiplying (A) the number of shares of Common Stock subject to this Warrant immediately prior to such Reorganization by (B) a fraction, the
numerator of which is the Fair Market Value per share of Common Stock as of the effective date of such Reorganization, as determined pursuant to subsection 1(b)(ii), and the denominator of which is the fair market value per share of common stock of
the acquiring or surviving company as of the effective date of such transaction, as determined in good faith by the Board (using the principles set forth in subsection 1(b)(ii) to the extent applicable), and (ii) the exercise price per
share of common stock of the acquiring or surviving company shall be the Purchase Price divided by the fraction referred to in clause (B) above. In any such case, appropriate adjustment (as determined in good faith by the Board) shall be made
in the application of the provisions set forth herein with respect to the rights and interests thereafter of the Registered Holder, to the end that the provisions set forth in this Section 2 (including provisions with respect to changes in and
other adjustments of the Purchase Price) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities, cash or other property thereafter deliverable upon the exercise of this Warrant. 
 (f) Certificate as to Adjustments. Upon the occurrence of each adjustment or readjustment of the Purchase Price pursuant to this Section 2,
the Company at its expense shall, as promptly as reasonably practicable but in any event not later than ten (10) days thereafter, compute such adjustment or readjustment in accordance with the terms hereof and furnish to the Registered Holder a
certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property for which this Warrant shall be exercisable and the Purchase Price) and showing in detail the facts upon which such
adjustment or readjustment is based. The Company shall, as promptly as reasonably practicable after the written request at any time of the Registered Holder (but in any event not later than ten (10) days thereafter), furnish or cause to be
furnished to the Registered Holder a certificate setting forth (i) the Purchase Price then in effect and (ii) the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received
upon the exercise of this Warrant. 
 3. Fractional Shares. The Company shall not be required upon the exercise of this Warrant to
issue any fractional shares, but shall pay the value thereof to the Registered Holder in cash on the basis of the Fair Market Value per share of Common Stock, as determined pursuant to subsection 1(b)(ii) above. 
 4. Investment Representations. The Registered Holder represents and warrants to the Company as follows: 
 (a) Investment. The Registered Holder is acquiring the Warrant, and (if and when it exercises this Warrant) it will acquire the Warrant Shares for
its own account for 

  

 - 5 - 

 
investment and not with a view to, or for sale in connection with, any distribution thereof, nor with any present intention of distributing or selling the
same. The Registered Holder has no present or contemplated agreement, undertaking, arrangement, obligation, indebtedness or commitment providing for the disposition thereof. 
 (b) Restricted Securities. The Registered Holder acknowledges that the Warrant and Warrant Shares consist of restricted securities that are
unregistered; that the Warrants and, when issued, the Warrant Shares may not be sold, transferred, or otherwise disposed of without registration under the Securities Act of 1933, as amended (the “Securities Act”) unless an exemption from
such registration is available; that in the absence of an effective registration statement covering the Warrant and, when issued, the Warrant Shares or an available exemption from registration under the Securities Act, the Warrant and, when issued,
the Warrant Shares must be held indefinitely. In particular, the Registered Holder is aware that the Warrants and, when issued, the Warrant Shares may not be sold pursuant to Rule 144 promulgated under the Securities Act unless all of the conditions
of that Rule are met and that among the conditions for use of Rule 144 may be the availability of current information to the public about the Company, information that is not now made available. The Registered Holder understands that the Warrants
and, when issued, Warrant Shares will be subject to the restrictions on exercise, conversion and transfer as set forth in the instruments governing such Warrants and, when issued, the Warrant Shares and in the Ancillary Agreements (as such term is
defined in the Series D Convertible Preferred Stock Purchase Agreement, dated as of September 4, 2007, by and among the Company and the purchasers named therein (the “Series D Purchase Agreement”)). 
 (c) Economic Risk; Sophistication. The Registered Holder is able to bear the economic risk of an investment in the Warrant acquired by him, her or
it pursuant to the terms of this Warrant and has sufficient knowledge and experience in financial and business matters that he, she or it is capable of evaluating the merits and risks of the proposed investment in the Company and the Registered
Holder is able financially to bear the risks thereof. The Company has made available to the Registered Holder or its representatives all agreements, documents, records and books that the Registered Holder has requested relating to an investment in
the securities to be acquired by the Registered Holder under the terms of this Warrant. The Registered Holder has had an opportunity to ask questions of, and receive answers from, a person or persons acting on behalf of the Company, concerning the
terms and conditions of this investment, and answers have been provided to all of such questions to the full satisfaction of the Registered Holder. 
 (d) Accredited Investor. The Registered Holder meets the criteria of an “accredited investor” as defined in Rule 501(a) of Regulation D adopted under the Securities Act (an “Accredited Investor”). 
 5. Transfers, etc. 
 (a) This Warrant
and, when issued, the Warrant Shares shall not be sold or transferred unless either (i) they first shall have been registered under the Act, or (ii) the Company first shall have been furnished with an opinion of legal counsel, reasonably
satisfactory to the Company, to the effect that such sale or transfer is exempt from the registration 

  

 - 6 - 

 
requirements of the Act. Notwithstanding the foregoing, no registration or opinion of counsel shall be required for (x) a transfer by a Registered
Holder to any other person or entity, for as long as such other person or entity is controlled by such Registered Holder, for as long as such other person or entity (directly or indirectly) controls such Registered Holder, for as long as such other
person or entity is in common control with such Registered Holder or for as long as such company is an investment fund or similar entity managed by one or more investment managers of such Registered Holder or managed by the same general partner or
manager as such Registered Holder or by any other general partner or manager within the same group of such Registered Holder or its general partner, provided that the transferee in each case agrees in writing to be subject to the terms of
this Warrant, or (y) a transfer made in accordance with Rule 144 under the Act. 
 (b) Each certificate representing Warrant Shares
shall bear a legend substantially in the following form: 
 “THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR
ANY STATE SECURITIES LAWS AND MAY NOT BE TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS IT HAS BEEN REGISTERED UNDER SUCH ACT AND ALL SUCH APPLICABLE LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE.” 
 The foregoing legend shall be removed from the certificates representing any Warrant Shares, at the request of the holder thereof, at such time as they
become eligible for resale pursuant to Rule 144(k) under the Act. 
 (c) The Company will maintain a register containing the name and
address of the Registered Holder of this Warrant. The Registered Holder may change its address as shown on the warrant register by written notice to the Company requesting such change. 
 (d) Subject to the provisions of Section 5 hereof, this Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of
this Warrant with a properly executed assignment (in the form of Exhibit II hereto) at the principal office of the Company (or, if another office or agency has been designated by the Company for such purpose, then at such other office or
agency). 
 6. No Impairment. The Company will not, by amendment of its charter or bylaws or through any reorganization, transfer of
assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the
carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the Registered Holder against impairment. 
 7. Notices of Record Date, etc. In the event: 
 (a) the Company shall take a record of the holders of its Common Stock (or other stock or securities at the time deliverable upon the exercise of this Warrant) for the purpose of entitling or enabling them to receive any dividend or other
distribution, or to receive any right to subscribe for or purchase any shares of stock of any class or any other securities, or to receive any other right; or 
  

 - 7 - 

 (b) of any capital reorganization of the Company, any reclassification of the Common Stock of the
Company, any consolidation or merger of the Company with or into another corporation, or any transfer of all or substantially all of the assets of the Company; or 
 (c) of the voluntary or involuntary dissolution, liquidation or winding-up of the Company, then, and in each such case, the Company will send or cause to be sent to the Registered Holder a notice specifying, as the
case may be, (i) the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii) the effective date on which such reorganization, reclassification, consolidation,
merger, transfer, dissolution, liquidation or winding-up is to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other stock or securities at the time deliverable upon the exercise of this
Warrant) shall be entitled to exchange their shares of Common Stock (or such other stock or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution,
liquidation or winding-up. Such notice shall be sent at least ten (10) days prior to the record date or effective date for the event specified in such notice. 
 8. Reservation of Stock. The Company will at all times reserve and keep available, solely for issuance and delivery upon the exercise of this Warrant, such number of Warrant Shares and other securities, cash
and/or property, as from time to time shall be issuable upon the exercise of this Warrant. 
 9. Exchange or Replacement of Warrants.

 (a) Upon the surrender by the Registered Holder, properly endorsed, to the Company at the principal office of the Company, the Company
will, subject to the provisions of Section 5 hereof, issue and deliver to or upon the order of the Registered Holder, at the Company’s expense, a new Warrant or Warrants of like tenor, in the name of the Registered Holder or as the
Registered Holder (upon payment by the Registered Holder of any applicable transfer taxes) may direct, calling in the aggregate on the face or faces thereof for the number of shares of Common Stock (or other securities, cash and/or property) then
issuable upon exercise of this Warrant. 
 (b) Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement (with surety if reasonably required) in an amount reasonably satisfactory to the Company, or (in the case of
mutilation) upon surrender and cancellation of this Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor. 
 10.
Notices. All notices and other communications from the Company to the Registered Holder in connection herewith shall be mailed by certified or registered mail, postage prepaid, or sent via a reputable international overnight courier service
guaranteeing next business day delivery, to the address last furnished to the Company in writing by the Registered Holder. 

  

 - 8 - 

 
All notices and other communications from the Registered Holder to the Company in connection herewith shall be mailed by certified or registered mail,
postage prepaid, or sent via a reputable international overnight courier service guaranteeing next business day delivery, to the Company at its principal office set forth below. If the Company should at any time change the location of its principal
office to a place other than as set forth below, it shall give prompt written notice to the Registered Holder and thereafter all references in this Warrant to the location of its principal office at the particular time shall be as so specified in
such notice. All such notices and communications shall be deemed delivered (i) three (3) business days after being sent by certified or registered mail, return receipt requested, postage prepaid, or (ii) one (1) business day
after being sent via a reputable international overnight courier service guaranteeing next business day delivery. 
 11. No Rights as
Stockholder. Until the exercise of this Warrant, the Registered Holder shall not have or exercise any rights by virtue hereof as a stockholder of the Company. Notwithstanding the foregoing, in the event (i) the Company effects a split of
the Common Stock by means of a stock dividend and the Purchase Price of and the number of Warrant Shares are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), and (ii) the
Registered Holder exercises this Warrant between the record date and the distribution date for such stock dividend, the Registered Holder shall be entitled to receive, on the distribution date, the stock dividend with respect to the shares of Common
Stock acquired upon such exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend. 
 12. Issue Tax. The issuance of certificate(s) for the Warrant Shares upon the exercise of this Warrant shall be made without charge to the Registered Holder for any issuance tax in respect thereto; provided
that, the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name other than that of the Holder. 
 13. Amendment or Waiver. This Warrant is one of a series of Warrants issued by the Company,
all dated as of a Closing Date (as such term is defined in the Series D Purchase Agreement) and of like tenor, except as to the number of shares of Common Stock subject thereto (collectively, the “Company Warrants”). Any term of this
Warrant may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) with the written consent of the Company and the holders of Company Warrants representing at least two-thirds (66 2/3%) of the number of shares of Common Stock then subject to outstanding Company Warrants. Notwithstanding the
foregoing, (a) this Warrant may be amended and the observance of any term hereunder may be waived without the written consent of the Registered Holder only in a manner which applies to all Company Warrants in the same fashion and (b) the
number of Warrant Shares subject to this Warrant and the Purchase Price of this Warrant may not be amended, and the right to exercise this Warrant may not be waived, without the written consent of the Registered Holder (it being agreed that an
amendment to or waiver under any of the provisions of Section 2 of this Warrant shall not be considered an amendment of the number of Warrant Shares or the Purchase Price). The Company shall give prompt written notice to the Registered Holder
of any amendment hereof or waiver hereunder that was effected without the Registered Holder’s written consent. No waivers of any term, condition or provision of this Warrant, in any one or more instances, shall be deemed to be, or construed as,
a further or continuing waiver of any such term, condition or provision. 
  

 - 9 - 

 14. Section Headings. The section headings in this Warrant are for the convenience of the parties
and in no way alter, modify, amend, limit or restrict the contractual obligations of the parties. 
 15. Governing Law. This Warrant
and any claim, controversy or cause of action (whether in contract or tort) based upon, arising out of or relating to this Warrant shall be governed by the substantive laws of the State of Delaware, without regard to its principles of conflicts of
laws that would result in the application of any law other than the law of the State of Delaware. 
 16. Facsimile Signatures. This
Warrant may be executed by facsimile signature. 
 Remainder of Page Left Intentionally Blank 
  

 - 10 - 

 EXECUTED as of the Date of Issuance indicated above. 
  

			
	ELIXIR PHARMACEUTICALS, INC.
		
	By:	 	  

	Name:	 	William K. Heiden
	Title:	 	President and Chief Executive Officer

 Signature Page to Warrant 

 EXHIBIT I 
 PURCHASE FORM 
  

													
	To:	 	  
	 		 		 		  	Dated:	  	  

 The undersigned, pursuant to the provisions set forth in the attached Warrant
(No.         ), hereby elects to purchase (check applicable box): 
  ̈               shares of the Common Stock of Elixir Pharmaceuticals, Inc.
covered by such Warrant; or 
  ̈      the maximum number of shares of Common Stock covered by such Warrant pursuant to the cashless exercise procedure set forth in subsection 1(b). 
 The undersigned herewith makes payment of the full purchase price for such shares at the price per share provided for in such Warrant. Such payment takes
the form of (check applicable box or boxes): 
  

	 	 ̈	$             in lawful money of the United States; and/or 

  

	 	 ̈	the cancellation of such portion of the attached Warrant as is exercisable for a total of          Warrant Shares (using a Fair Market
Value of $         per share for purposes of this calculation) ; and/or 

  

	 	 ̈	the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 1(b), to exercise this Warrant with respect to the
maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 1(b). 

  

			
	 Signature:
	 	  

		
	 Address:
	 	  

		
		 	  

 EXHIBIT II 
 ASSIGNMENT FORM 
 FOR VALUE RECEIVED,
                                        
                                        
hereby sells, assigns and transfers all of the rights of the undersigned under the attached Warrant (No.         ) with respect to the number of shares of Common Stock of Elixir Pharmaceuticals, Inc.
covered thereby set forth below, unto: 
  

					
	 Name of Assignee
	  	 Address
	  	 No. of Shares

  
  

									
	 Dated:
	 	                             	 		 	Signature:	  	  

				
	 Signature Guaranteed:
	 		 		  	
					
	 By:
	 	  
	 		 		  	

 The signature should be guaranteed by an eligible guarantor institution (banks, stockbrokers, savings and loan
associations and credit unions with membership in an approved signature guarantee medallion program) pursuant to Rule 17Ad-15 under the Securities Exchange Act of 1934.Agency  Agreement with Compton Overseas Investment

 Exhibit 10.34 
 AGENCY AGREEMENT 
 BETWEEN ELIXIR PHARMACEUTICALS, INC. AND COMPTON OVERSEAS INVESTMENT LTD. 
 1. APPOINTMENT 
 Reference is hereby made to that
certain Agency Agreement by and between Elixir Pharmaceuticals, Inc. of 12 Emily Street Cambridge, MA 02139 (the “Company”) and Compton Overseas Investment Ltd. of P.O. Box 22166, Riyadh, Saudi Arabia (the “Agent”), dated as of
June 20, 2006 (the “Series C Agency Agreement”), which agreement is superseded in its entirety by this Agreement. In consideration of the mutual promises herein contained and other good and valuable consideration, the Company hereby
appoints and authorizes the Agent on a non-exclusive basis to introduce the Company to one or more persons or entities (each an “Investor” and collectively, the “Investors”) for the purpose of investment in the Series D
Convertible Preferred Stock of the Company, par value $.001 per share (the “Series D Stock”), and the Agent hereby accepts such appointment, to be carried out by the Agent in accordance with applicable laws and regulations and the terms of
this Agreement. Without limiting the foregoing, the Agent will (A) contact Investors who are not U.S. Persons (as defined below) only within jurisdictions in which (i) the Agent or an affiliated entity of the Agent is registered as a
broker-dealer, or (ii) the Agent is otherwise qualified in such jurisdiction to make such contact, or (iii) such contact will not violate applicable law and (B) contact Investors who are U.S. Persons only if the Agent or an affiliated
entity is registered under United States federal law and the applicable laws of the state(s) in which such Investor is a resident and/or in which the offer and sale of the Series D Stock occur. As used in this Agreement, “U.S. Person” has
the meaning set forth in Rule 902 of Regulation S adopted under the Securities Act of 1933, as amended (the “Act”). 
 2. TERRITORY AND
INTRODUCTIONS 
  

	 	(a)	Except as otherwise provided herein, the Agent’s areas of primary responsibility under this Agreement are global. 

  

	 	(b)	 After the Agent has located a potential interested Investor, and prior to introducing the Company to the potential Investor, the Agent shall provide the Company
with such potential Investor’s name, location, and whether the Investor is an independent venture capital corporation or a corporate venture capital corporation or if neither, its capability. In addition, the Agent shall provide the Company
with a list of all the individuals who are direct and indirect beneficial owners of such potential Investor (the “Investor Information”). The Company will identify to the Agent within ten (10) business days after receipt of the
Investor Information whether such identified 

	 	 
potential Investor shall thereafter be qualified as either an Existing Approved Investor (as defined below) or a New Approved Investor (as defined below)
(collectively, an “Approved Investor”) for the purposes of this Agreement. If there is no communication from the Company after ten (10) business days from receipt of the Investor Information, such identified potential Investor(s) will
not be qualified as an “Approved Investor” for the purposes of this Agreement. An “Existing Approved Investor” shall include an individual potential Investor or, in the aggregate, a group of more than one potential Investors
where each individual potential Investor in the group has been qualified as an Approved Investor pursuant to the terms of the Series B Agency Agreement or the the Series B Agency Agreement and the terms of this Agreement and has invested in the
Series B Convertible Preferred Stock of the Company, par value $.001 per share, or the Series B Convertible Preferred Stock of the Company, par value $.001 per share, qualified by the Company as set forth above. A “New Approved Investor”
shall also include an individual potential Investor or, in the aggregate, a group of more than one potential Investors where each individual potential Investor in the group has been qualified as an Approved Investor and who has not previously
invested in the Company as of the date hereof. For the avoidance of doubt, in the event that Agent introduces a group of more than one potential Investor that includes Existing Approved Investors and New Approved Investors, such group will be
considered an Existing Approved Investor. 

  

	 	(c)	If the Company qualifies a potential Investor as an Approved Investor pursuant to the foregoing paragraph, the Agent may, at the Company’s request, arrange meetings between the
Company and such Approved Investor. The Agent shall not make any representation or warranty regarding the Company, nor provide an Investor with any materials relating to the Company not approved in advance by the Company. 

 

	 	(d)	The Company and Approved Investor shall negotiate the terms and conditions of an agreement, if any, between the Company and such Approved Investor with respect to the proposed
investment in the capital stock of the Company. 

  

	 	(e)	During the term of this Agreement and the three (3) year period following the initial purchase of Series D Stock by any Approved Investor and prior to the effectiveness of a
registration statement filed with respect to the Company’s initial public offering (“IPO”), the Company will notify the Agent in writing within fifteen (15) days of any such Approved Investor’s purchase of capital stock of
the Company. 

  

	 	(f)	 The Agent acknowledges that the securities of the Company to be issued hereunder to the Agent or that may be sold to Approved Investors have not been registered
under the Act and it is intended that securities sold to Approved Investors shall not be required to be registered under the Act by virtue of an exemption from registration thereunder. The Agent acknowledges that it is 

	 	 
familiar with the Act and Regulation D and Regulation S promulgated thereunder. The Agent agrees that with respect to Investors who are U.S. Persons, it
will only introduce the Company to prospective Investors with whom either it or the Company have a substantive pre-existing relationship so as to comply with the relevant requirements of Regulation D, to the extent applicable. In making
introductions, the Agent shall not engage in any form of general solicitation or general advertising, including but not limited to any advertisement, article, notice or communication published in any newspaper, magazine or similar media or broadcast
over television or radio or transmitted by any electronic means, or any meetings or seminars (except for meetings with individual investors). The Agent will introduce to the Company only “accredited investors,” as that term is defined in
Rule 501 under the Act and will exercise reasonable care to ensure that the purchasers of the Securities are not underwriters within the meaning of Section 2(11) of the Act. 

 3. COMPENSATION 
 The Agent’s compensation for
all services performed hereunder, in the context of a strict agency relationship, shall be as follows: 
  

	 	(a)	Applicable Compensation: 

 The following
compensation (the “Applicable Compensation”) will be paid by the Company upon the issuance and sale to an Approved Investor or Approved Investors of shares of capital stock of the Company, including shares of Series D Stock, as a result of
an introduction by the Agent: 
 (i) the Company will deliver to the Agent common stock of the Company, par value $.001 per share
(“Common Stock”), equal to 3.0% of the amount of such capital stock purchased by Existing Approved Investors, plus one or more warrants (“Warrants”) to purchase in the aggregate up to an additional 1.0% of the aggregate amount of
Common Stock purchased by the Existing Approved Investors; provided that such Existing Approved Investors individually or in the aggregate purchase at least $500,000 of such capital stock; and 
 (ii) the Company will deliver to the Agent Common Stock equal to 5.0% of the amount of such capital stock purchased by New Approved Investors, plus one or
more Warrants to purchase in the aggregate up to an additional 1.5% of the aggregate amount of Common Stock purchased by the New Approved Investors; provided that such New Approved Investors individually or in the aggregate purchase at least
$500,000 of such capital stock. 
 With the consent of the Company, the Agent may allocate a portion of its compensation to a third party or
parties by so notifying the Company at the time of the sale and issuance of capital stock to the Approved Investors; provided, however, that the Agent may not do so unless payments by the Company to such third party would not violate any applicable
law, rule, regulation or administrative requirement. 

	 	(b)	Warrants: 

 Any Warrants issued by the Company
pursuant to paragraph 3(a)(i) or 3(a)(ii) shall have the same rights and obligations and be in substantially the same form as the warrants received by Investors pursuant to the Series D Purchase Agreement. Notwithstanding the foregoing, all Warrants
issued to the Agent by the Company hereunder shall expire immediately prior to the earlier of (i) effectiveness of a registration statement filed with respect to the Company’s initial public offering of stock, or (ii) the merger,
consolidation, sale of substantially all of the assets, or sale of more than a majority of the outstanding voting stock of the Company, provided, however, that in the case of the occurrence of the events described in items (i) and
(ii) of this subsection, the Company shall give the Agent notice of such pending event(s) and the Agent shall have at least seven (7) days following receipt of such notice to exercise all or some of such Warrant(s) prior to their expiry.
As a condition to receiving any Warrants hereunder, the Agent shall provide such documentation as may be reasonably requested by Company to establish that the Agent is an accredited investor. 
  

	 	(c)	Reinvestment Fees:  

 Following the final closing of
the Company’s issuance and sale of Series D Stock pursuant to the Series D Convertible Stock Purchase Agreement (the “Series D Purchase Agreement”) by and among the Company and the purchasers set forth therein (such closing being
referred to as the “Series D Closing”), the Company agrees to pay to the Agent the Applicable Compensation described in paragraphs 3(a)(i) and 3(a)(ii) above if and then only to the extent that any Approved Investor purchases additional
shares of capital stock of the Company within two (2) years of such Approved Investor’s initial purchase of Series D Stock and prior to the effectiveness of a registration statement filed with respect to the Company’s IPO. If there
are any such purchases after two (2) years but within three (3) years of such Approved Investor’s initial purchase of Series D Stock and prior to the effectiveness of a registration statement filed with respect to the Company’s
IPO, the Company agrees to pay the Agent 50% of the Applicable Compensation described in paragraphs 3(a)(i) and 3(a)(ii) above. Any reinvestment fee will only be paid on new purchases, and prior purchases will not count towards meeting the payment
thresholds described in paragraphs 3(a)(i) and 3(a)(ii) above. 
 4. PAYMENT OF COMPENSATION 
 The Applicable Compensation described in Section 3 above shall be delivered to the Agent within ninety (90) days of the closing of the financing
round with respect to which such Applicable Compensation is payable. 

 5. AGENT’S RELATIONSHIP TO COMPANY 
 The Agent shall be free at all times to conduct its business in such manner as it may see fit, consistent with the terms and conditions of this Agreement.
The Agent may allocate whatever portion of its time to the introductions contemplated hereunder as the Agent may deem proper and may operate on the Agent’s own schedule, provided that the Agent uses reasonable efforts to fulfill its obligations
hereunder. 
 The Agent shall have no power to bind the Company. The Company shall be solely responsible for negotiating, entering into and
enforcing the terms of any agreement with an Investor. The Company may refuse to sell its capital stock to any Investor, whether or not an Approved Investor and with or without reason, without incurring any fee or other compensation to the Agent
with respect thereto. 
 6. TERM OF AGREEMENT 
 This Agreement shall take effect on the date of signature by the Company and the Agent below and shall continue in effect until the earlier of either (i) the completion of the Series D Closing, or (ii) one (1) year from the
date of execution by both parties, subject to termination by either the Company or the Agent with thirty (30) days notice so long as the terminating party is not in material breach of this Agreement. Sections 3, 4 and 7 will survive
expiration of this Agreement. In the event of a material breach by the Agent, the Company may terminate this Agreement effective sixty (60) days after written notice of such breach to the Agent and failure to cure such breach by the Agent
within sixty (60) days in which case no reinvestment fees shall be payable by the Company. 
 7. REPRESENTATIONS, WARRANTIES AND COVENANTS

 A. Company acknowledges, represents and warrants that: 
 (i) It has full power and authority to enter into and perform in accordance with the terms of this Agreement; and 
 (ii) The information provided to the Agent to furnish to Approved Investors in connection with introductions made hereunder is true and correct to the best of the Company’s knowledge and belief. 
 B. The Agent acknowledges, represents and warrants that: 
 (i) It has full power and authority to enter into and perform in accordance with the terms of this Agreement; 
 (ii) In furtherance of the Company’s efforts to comply with all applicable laws concerning money laundering and related activities, and to the best of the Agent’s knowledge after appropriate diligence and investigation:

 (1) None of the cash or property that the Investors has paid, will pay or will contribute to the Company in exchange for
shares of Series D Stock has been 

 
or shall be derived from, or related to, any activity that is deemed unlawful under United States federal or state laws, including, without limitation, the
Foreign Corrupt Practices Act of 1977, as amended; and 
 (2) No contribution or payment by the Investors to the Company, to
the extent that they are within the Investors’ control, shall cause the Company to be in violation of the United States Bank Secrecy Act, the United States Money Laundering Control Act of 1986 or the United States International Money Laundering
Abatement and Anti-Terrorist Financing Act of 2001, each as amended from time to time, including pursuant to the USA PATRIOT Act of 2001; 
 (iii) The Agent shall promptly notify the Company if it subsequently becomes aware any of the representations set forth in (ii) above cease to be true and accurate regarding any Investor; and 
 (iv) No Investor contacted by the Agent in connection with the Agent’s performance hereunder is a “supporter” of terrorist organizations
listed by the U.S. federal government pursuant to Executive Order 13224 nor do they appear on or are covered by any other lists of prohibited persons, entities, and jurisdictions maintained and administered by the U.S. Treasury Department’s
Office of Foreign Assets Control, each as updated and/or amended from time to time. 
 8. INDEMNIFICATION 
 Each party agrees to indemnify and hold the other party, together with its respective affiliates, directors, officers, employees and controlling persons
(the “Indemnified Party”) harmless from any loss, damage, liability or expense, including reasonable attorneys’ fees and other legal expenses, to which the Indemnified Party may become subject arising from a claim that results from a
breach of this Agreement by the other party to this Agreement. In addition, the Agent agrees to indemnify and hold the Company, together with its respective affiliates, directors, officers, employees and controlling persons, harmless in connection
with any claim for compensation by any party other than the Agent for services relating to an Approved Investor where compensation for such services is payable or has been paid to the Agent. 
 9. CONFIDENTIALITY 
 The Agent recognizes that the
Company’s business interests require a confidential relationship between the Company and the Agent and the fullest practical protection and confidential treatment of proprietary, confidential, intellectual and other property owned by the
Company and consisting of information embodied in documents that may be given to the Agent in the course of its association with the Company (collectively termed the “Information”). Except insofar as is authorized in writing by the Company
or required by applicable law, the Agent agrees that: (i) it 

 
will not use any of the Information for its own account, (ii) it will not disclose any of the Information to others, except in furtherance of the
objectives of this Agreement, and (iii) it will not make or disclose documents or copies of documents embodying or containing disclosures of any of the Information, except as permitted by and in furtherance of the objectives of this engagement.
The parties further agree that the terms of this agreement shall remain confidential unless otherwise agreed in writing by the parties or as required by applicable law, provided, however, that this sentence shall not apply to information
related to the tax treatment or the tax structure of the transactions contemplated herein and to information requested by regulators. For this purpose, “tax structure” is limited to any facts relevant to the U.S. federal income tax
treatment of the transaction and does not include information relating to the identity of the parties. 
 10. MISCELLANEOUS 
  

	 	(a)	This Agreement represents the entire understanding between these parties pertaining to the subject matter contained herein and merges all prior and contemporaneous communications
between the parties. No supplement, modification, representation, waiver or amendment of this Agreement shall be binding on either party unless expressly agreed to by both parties in writing. This Agreement shall be binding upon and inure to the
benefit of the parties’ successors and assigns. 

  

	 	(b)	Notices shall be delivered by airmail, facsimile or courier to the other party at their respective addresses set forth above. 

  

	 	(c)	This Agreement shall be construed under and governed by the laws of the Commonwealth of Massachusetts. 

 [signatures follow] 

 The parties hereby execute this Agency Agreement as of this 4th day of September, 2007. 
  

							
	ELIXIR PHARMACEUTICALS, INC.	  	COMPTON OVERSEAS INVESTMENT LTD.
				
	Date:	 	September 4, 2007	  	Date:	 	August 28, 2007
	By:	 	 /s/ William K. Heiden
	  	By:	 	 /s/ Vernon Cassin

	Title:	 	President and CEO	  	Title:	 	Director
	Facsimile:	 	  
	  	Facsimile:	 	+ 966-1-462-9001

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]